PASTEUR Act of 2026

This bill would let the Secretary of Health and Human Services sign contracts with makers of new antimicrobial drugs that treat drug-resistant bacterial or fungal infections. Drugs would be scored on patient benefit, innovation, and public health value, and approved contracts would pay between $75 million and $300 million per year, reduced by the drug's U.S. sales, for up to 10 years. In return, drugmakers would have to keep the drug available in the U.S., report resistance data, and submit plans for appropriate use. The bill would also create a 15-member advisory group, fund grants for hospitals and outpatient clinics to manage antibiotic use, expand federal tracking of drug resistance, and provide $6 billion for these efforts.

Full text and official record on Congress.gov

Sponsors

• Earl L. "Buddy" Carter Republican sponsor
• 29 cosponsors